home / stock / scyx / scyx quote
Last: | $1.55 |
---|---|
Change Percent: | -2.78% |
Open: | $1.48 |
Close: | $1.55 |
High: | $1.6058 |
Low: | $1.48 |
Volume: | 151,685 |
Last Trade Date Time: | 04/23/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.55 | $1.48 | $1.55 | $1.6058 | $1.48 | 151,685 | 04-23-2024 |
$1.44 | $1.45 | $1.44 | $1.48 | $1.44 | 72,655 | 04-22-2024 |
$1.44 | $1.41 | $1.44 | $1.4699 | $1.39 | 130,980 | 04-19-2024 |
$1.405 | $1.43 | $1.405 | $1.477 | $1.39 | 79,920 | 04-18-2024 |
$1.42 | $1.4 | $1.42 | $1.46 | $1.37 | 127,425 | 04-17-2024 |
$1.41 | $1.47 | $1.41 | $1.5 | $1.4 | 106,303 | 04-16-2024 |
$1.47 | $1.49 | $1.47 | $1.52 | $1.43 | 128,518 | 04-15-2024 |
$1.445 | $1.61 | $1.445 | $1.63 | $1.44 | 496,787 | 04-12-2024 |
$1.6 | $1.61 | $1.6 | $1.61 | $1.55 | 144,836 | 04-11-2024 |
$1.58 | $1.6 | $1.58 | $1.63 | $1.56 | 144,685 | 04-10-2024 |
$1.63 | $1.66 | $1.63 | $1.67 | $1.58 | 156,160 | 04-09-2024 |
$1.63 | $1.72 | $1.63 | $1.72 | $1.61 | 172,242 | 04-08-2024 |
$1.71 | $1.69 | $1.71 | $1.79 | $1.6701 | 125,497 | 04-05-2024 |
$1.68 | $1.78 | $1.68 | $1.86 | $1.6101 | 320,762 | 04-04-2024 |
$1.8 | $1.55 | $1.8 | $1.85 | $1.54 | 724,503 | 04-03-2024 |
$1.45 | $1.46 | $1.45 | $1.58 | $1.41 | 266,616 | 04-02-2024 |
$1.49 | $1.52 | $1.49 | $1.525 | $1.42 | 284,073 | 04-01-2024 |
$1.47 | $1.42 | $1.47 | $1.52 | $1.42 | 184,086 | 03-29-2024 |
$1.47 | $1.42 | $1.47 | $1.52 | $1.42 | 184,086 | 03-28-2024 |
$1.425 | $1.41 | $1.425 | $1.46 | $1.4 | 107,777 | 03-27-2024 |
News, Short Squeeze, Breakout and More Instantly...
JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to o...
JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second-genera...
SCY-247’s IND-enabling activities continue to advance with initiation of Phase I anticipated in the second half of 2024 Data analysis for the FURI study is ongoing; top line data from the CARES study has been received and is positive and consistent with previously disclosed results...